Compare MLYS & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | IRMD |
|---|---|---|
| Founded | 2019 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.1B |
| IPO Year | 2023 | 2014 |
| Metric | MLYS | IRMD |
|---|---|---|
| Price | $29.55 | $86.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $48.67 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 1.1M | 84.5K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | ★ 37.43 | 16.67 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $83,814,000.00 |
| Revenue This Year | N/A | $12.38 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $95.88 |
| Revenue Growth | N/A | ★ 14.43 |
| 52 Week Low | $22.30 | $67.84 |
| 52 Week High | $47.65 | $107.90 |
| Indicator | MLYS | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 35.98 |
| Support Level | $25.56 | $82.25 |
| Resistance Level | $31.36 | $88.93 |
| Average True Range (ATR) | 1.60 | 1.98 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 50.56 | 20.35 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.